Diabetes Pen Companies | Market Research Future

Top Industry Leaders in the Global Diabetes Pen Market

Diabetes Pen Key Companies.jpg Latest Diabetes Pen Companies Update

March 2023: Eli Lilly and Company introduced price reductions of 70% for its most frequently prescribed insulins, along with an extension of its Insulin Value Program, which restricts monthly patient out-of-pocket expenses to $35 or less. Lilly is undertaking these measures to facilitate access to its insulin and assist individuals in the United States who may encounter challenges in traversing a complex healthcare system, which could impede their ability to obtain affordable insulin. Although the existing healthcare system grants insulin access to the majority of individuals with diabetes, it continues to fail to offer affordable insulin to all; this must alter. Lilly has devoted the last century to the development of novel and enhanced insulins and other pharmaceuticals designed to mitigate the effects of diabetes and enhance patient prognoses.

November 2023: USV Pvt. Ltd., an industry leader in oral anti-diabetes medications, introduced INSUQUICK, the first biosimilar insulin aspart available in India, in November 2023. INSUQUICK is intended for the treatment of individuals with diabetes. DCGI has granted approval to INSUQUICK® for the management of glycemic control in diabetic patients. The INSUQUICK® VDPen is a disposable, prefilled variable dose pen injector with audible sounds for precise incremental settings, a lightweight, large legible scale, and a modern, robust design. Additionally, USV has introduced USVPen®, a reusable pen specifically engineered to be used with its range of insulin. Insulin is delivered precisely with USVPen®'s minimal dose force, rendering it an intuitive device. A product of over a decade of nonstop R&D, INSUQUICK® is comprised entirely of indigenous robust technology that ensures comprehensive cold chain management.

List of Diabetes Pen Key companies in the market